Insulin-releasing ‘smart cells’ could inspire new diabetes treatment

Diabetes paraphernalia
Scientists in North Carolina hope the skin patch they're developing will offer diabetes patients an alternative to frequent, painful blood testing and insulin injections.

Patients with Type 1 diabetes know the routine all too well: the frequent skin pricks to test their blood, the need for insulin injections or a mechanical pump to prevent dangerous spikes or drops in blood sugar. Scientists at University of North Carolina and NC State are developing what they hope will be a less painful, more convenient alternative: “smart” artificial beta cells that can detect the need for insulin and secrete it automatically.

In Type 1 diabetes and some cases of the Type 2 form of the disease, the loss or malfunctioning of beta cells in the pancreas that secrete insulin is the culprit. So the researchers made versions of the cells that can be inserted under the skin and replaced every few days. In mouse models of diabetes, a single injection of the cells normalized blood sugar and kept levels steady for up to five days, they reported in the journal Nature Chemical Biology.

The cells are modeled after real beta cells in that they have membranes made of two levels of lipids. The research team then added special vesicles to the cells that contain insulin and that have a coating that changes chemically when blood sugar rises. That change prompts the cells to release insulin.


Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

RELATED: Insights into fat signaling could boost the fight against obesity and diabetes

The biotech industry has invested hundreds of millions of dollars into developing alternatives to frequent finger pricks and insulin injections—with limited success. MannKind launched its inhaled insulin product, Afrezza, in 2015, but sales were so disappointing that the company’s marketing partner, Sanofi, pulled out in 2016.

Medical device makers have had considerably more success developing products to simplify diabetes care. In June, for example, Medtronic won FDA approval for the MiniMed 670G, the first insulin pump that includes a built-in glucose sensor and that automatically dispenses the drug as needed. And in September, Abbot nabbed an FDA thumbs-up for FreeStyle Libre Flash, a wearable skin sensor that measures blood sugar without requiring finger pricks.

The North Carolina research team believes their smart beta cells could be administered via a painless, disposable skin patch. They are now developing a patch and planning more preclinical tests of their technology. Separately, they are also working on a smart patch that will work without cells to detect blood glucose and dispense insulin as needed.

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.